Reviewing MAESTRO-NASH and the implications for hepatology and health systems in implementation/accessibility of Resmetirom

• DOI: 10.1038/s44355-024-00017-5
• Publication Date: 2025-01-22T10:27:05Z
• Authors: Paul N. Brennan; Christopher J. Kopka; Leire Agirre-Garrido; Camila Dalby Hansen; Naim Alkhouri; Jörn M. Schattenberg; Dana Ivancovsky-W...; Scott Isaacs; Maurice Michel; Jeffrey V. Lazarus

Around 5.3% of adults worldwide are living with metabolic dysfunction-associated steatohepatitis (MASH). As liver fibrosis develops, their incidence of cirrhosis, hepatocellular carcinoma, cardiovascular complications, and non-liver cancer increases. We analyse MAESTRO-NASH resmetirom data and discuss real-world implications following approval. US-based patients now have a novel treatment and expert use recommendations. We anticipate that the UK and EU will approve resmetirom; however, questions remain regarding patient selection and implementation practice.<br/>Around 5.3% of adults worldwide are living with metabolic dysfunction-associated steatohepatitis (MASH). As liver fibrosis develops, their incidence of cirrhosis, hepatocellular carcinoma, cardiovascular complications, and non-liver cancer increases. We analyse MAESTRO-NASH resmetirom data and discuss real-world implications following approval. US-based patients now have a novel treatment and expert use recommendations. We anticipate that the UK and EU will approve resmetirom; however, questions remain regarding patient selection and implementation practice<br/>